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This data article contains a supplementary ﬁgure and validation
data relating to the research article entitled “Genotyping of wild-
type cytochrome P450 2A6 and whole-gene deletion using human
blood samples and a multiplex real-time polymerase chain reac-
tion method with dual-labeled probes” (Shimizu et al., Clinica
Chimica Acta 441, 71–74, 2015), which presents a multiplex real-
time polymerase chain reaction method with dual-labeled probes
for human P450 2A6wild-type and whole-gene deletion. Real-time
methods have dramatically improved the speed of complex genetic
diagnostics compared to conventional assays based on restriction
enzyme digestion. Here, we show the basic assay validation data
by single and multiplex determinations in comparison with com-
mercial TaqMan copy number assays for P450 2A6.
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Biologyore speciﬁc sub-
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xperimental
factorsHuman blood drop samples and DNA fractions obtained from 45 Japanese
individual subjects.xperimental
featuresA rapid detection assay of wild-type and whole-gene deletion-type of human
P450 2A6 by multiplex real-time polymerase chain reaction and commer-
cially available TaqMan assays for P450 2A6 copy number determinations
were validated.ata source
locationShowa Pharmaceutical University, Machida, Tokyo, Jc,apanata accessibility The data are supplied with this article.Value of the data1. A real-time polymerase chain reaction (PCR) assay for cytochrome P450 2A6 genotyping recently
developed [1] was fully validated using a conventional PCR-restriction fragment length poly-
morphism (RFLP) method (Fig. 1).
2. Aside from the PCR-based methods outlined in this report, commercially available TaqMan assays
for copy number determinations (whole-gene deletion P450 2A6*4 genotyping in regions of limited
homology) were almost validated (Table 1).
3. Genotyping strategies for P450 2A6 wild-type (P450 2A6*1) and whole-gene deletion (P450 2A6*4)
alleles deﬁned here could be combined with highly automated genome-wide association studies,
which have limited utility for identifying whole-gene deletions.
4. The dataset that supports the genotyping validations of human P450 2A6wild-type and whole gene
deletion are provided by single and multiplex determinations in comparison with commercial
TaqMan copy number assays.1. Data
Validation of genotyping of human wild-type P450 2A6*1 and whole-gene deletion P450 2A6*4 by
both PCR-RFLP and real-time platforms was carried out. One of the 45 subjects (genotyped as P450P450 2A6 genotype
Marker
image for genotyping of human P450 2A6 (P450 2A6*1A, 2A6*1B, and 2A6*4) by PCR-RFLP [2–4]
. The PCR products of P450 2A6*1A (1323 bp) and 2A6*1B (1322 bp) with a forward primer named
CCCTATGCTG-30) and a reverse primer named 2A6 UTR AS-1 (50-TGTAAAATGGGCATGAACGCCC-30)
into fragments of 573, 513, 148, and 89 bp and fragments of 661, 513, and 148 bp, respectively. The
(1309 bp) were digested by FokI into fragments of 661, 411, 148, and 89 bp.
Table 1
Comparison of genotyping of P450 2A6 of 45 individuals in a Japanese population by conventional PCR (Fig. 1), multiplex real-
time PCR [1], and three positions for TaqMan methods (07545274, 04488984, and 07545275).
PCR-
RFLP,
FokI
Multiplex
real-time
PCR
TaqMan PCR-
RFLP,
FokI
Multiplex
real-time
PCR
TaqMan
07545274 04488984 07545275 07545274 04488984 07545275
*1A/*1A *1/*1 1.8 1.9 2.4 *1B/*1B *1/*1 1.8 1.9 2.2
*1A/*1A *1/*1 2.0 1.9 2.3 *1B/*1B *1/*1 1.7 2.1 2.4
*1A/*1A *1/*1 1.8 2.1 2.4 *1B/*1B *1/*1 1.9 1.8 2.4
*1A/*1A *1/*1 2.0 2.0 2.0 *1B/*1B *1/*1 2.2 2.0 2.5
*1A/*1A *1/*1 2.0 2.1 2.1 *1B/*1B *1/*1 2.1 1.7 2.1
*1A/*1A *1/*1 2.2 2.3 2.3 *1B/*1B *1/*1 2.2 2.5 2.1
*1A/*1B *1/*1 1.8 1.6 1.7 *1B/*1B *1/*1 2.5 2.8 2.3
*1A/*1B *1/*1 1.9 2.0 2.4 *1B/*1B *1/*1 2.1 2.1 2.2
*1A/*1B *1/*1 2.1 2.1 2.2 *1B/*1B *1/*1 1.7 1.8 2.2
*1A/*1B *1/*1 2.2 1.8 2.4 *1A/*4 *1/*4 1.1 1.0 1.2
*1A/*1B *1/*1 1.9 1.9 2.0 *1A/*4 *1/*4 1.4 1.4 1.2
*1A/*1B *1/*1 1.9 2.0 2.4 *1A/*4 *1/*4 1.3 1.3 1.5
*1A/*1B *1/*1 1.8 1.9 2.2 *1A/*4 *1/*4 1.0 1.2 1.0
*1A/*1B *1/*1 1.9 2.3 2.4 *1A/*4 *1/*4 1.0 1.3 1.2
*1A/*1B *1/*1 1.5 1.9 2.5 *1B/*4 *1/*4 1.1 1.0 1.3
*1A/*1B *1/*1 2.1 2.0 2.5 *1B/*4 *1/*4 1.2 0.9 1.4
*1A/*1B *1/*1 2.1 2.5 1.7 *1B/*4 *1/*4 1.2 1.3 1.2
*1A/*1B *1/*1 2.0 2.3 2.5 *1B/*4 *1/*4 1.2 1.3 1.3
*1A/*1B *1/*1 1.9 2.3 2.5 *1B/*4 *1/*4 1.0 1.2 1.1
*1A/*1B *1/*1 2.0 2.0 2.0 *1B/*4 *1/*4 1.0 1.1 1.2
*1A/*1B *1/*1 1.7 2.2 1.7 *4/*4 *4/*4 0.1 0.1 0.1
*1B/*1B *1/*1 0.9 1.3 1.1 *4/*4 *4/*4 0.2 0.2 0.2
*1B/*1B *1/*1 1.6 1.9 2.2
Bold and italic copy numbers obtained by the TaqMan system were not consistent with the genotyping by conventional PCR and
multiplex real-time PCR [1]. A representative PCR-RFLP gel after FokI digestion for P450 2A6*1A, *1B and *4 are shown in Fig. 1.
M. Shimizu et al. / Data in Brief 5 (2015) 642–6456442A6*1B/*1B, Table 1) was not matched in term of P450 2A6 copy numbers (around 1) in the current
TaqMan analysis.2. Experimental design, materials and methods
The ethics committee of Showa Pharmaceutical University approved this analysis in accordance
with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent
was obtained for experimentation from all subjects. Genotyping of P450 2A6 (P450 2A6*1A, 2A6*1B,
and 2A6*4) was carried out by conventional PCR ampliﬁcation (Fig. 1) as described previously [2–4].
Blood samples were obtained with puncture needles, lysed, and stabilized [5]. Blood samples from
healthy non-smoking Japanese volunteers or DNA fractions extracted separately by the standard
protocol from the volunteers' buccal cells were used for real-time detection of P450 2A6 wild-type
and whole-gene deletion [1]. The samples also underwent TaqMan Copy Number Assays
(Hs07545274, Hs04488984, and Hs07545275; ThermoFisher Scientiﬁc, Waltham, MA, USA). The P450
2A6 copy numbers in the human genomes were calculated using CopyCaller software according to the
manufacturer's instructions with designed human RNase P TaqMan Copy Number Reference Assays
(4403326; ThermoFisher Scientiﬁc) after duplex real-time PCR reactions.Conﬂicts of interest
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